ReviewEuropean heart journal2006
Benefits, challenges, and registerability of the polypill.
Review in European heart journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01321255 (Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Medication burden in patients with dialysis-dependent CKD: a systematic review.Renal failure · 2024Pooled it
- European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).International journal of behavioral medicine · 2012Guideline
- Challenges and Opportunities in Managing Geriatric Depression: The Role of Personalized Medicine and Age-Appropriate Therapeutic Approaches.Pharmaceutics · 2024Review
- The polypill in the primary prevention of heart attacks and strokes: Overcoming barriers to implementation.Journal of medical screening · 2024Article
- A Review of the Benefits 3D Printing Brings to Patients with Neurological Diseases.Pharmaceutics · 2023Review
- Correlation of polypill and blood pressure level: A systematic review of clinical trials.Journal of education and health promotion · 2023Article
- 3D Printed Mini-Floating-Polypill for Parkinson's Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy.Pharmaceutics · 2022Article
- 3D Printing of Pharmaceutical Application: Drug Screening and Drug Delivery.Pharmaceutics · 2021Review
- "Development of Fixed Dose Combination Products" Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy.The AAPS journal · 2019Article
- Valvejet Technology for the Production of a Personalised Fixed Dose Combination of Ramipril and Glimepiride: an Investigative Study on the Stability of Ramipril.Pharmaceutical research · 2018Article
- The polypill approach - An innovative strategy to improve cardiovascular health in Europe.BMC pharmacology & toxicology · 2017Review
- Could patents interfere with the development of a cardiovascular polypill?Journal of translational medicine · 2016Article
- Article
- Assessing patterns of use of cardio-protective polypill component medicines in Australian women.Drugs & aging · 2013Article
- Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles.Bulletin of the World Health Organization · 2011Article
- Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management.Integrated blood pressure control · 2011Article
- Health-chair reform: your chair: comfortable but deadly.Diabetes · 2010Article
- Combination therapy in hypertension: An update.Diabetology & metabolic syndrome · 2010Article
- Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.Patient preference and adherence · 2010Article
- Issues to consider in the pharmaceutical development of a cardiovascular polypill.Nature clinical practice. Cardiovascular medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guidelines for the management of cardiovascular disease (CVD) stress the importance of treating global risk, rather than individual risk, factors. Patients at high cardiovascular (CV) risk, for example, benefit from a combination of aspirin, antihypertensive agents, lipid-lowering drugs, and possibly folic acid. As the number of medications that a patient requires increases, adherence and compliance to therapy are likely to decrease. The use of affordable, multiple-target, fixed-combination 'polypills', which concomitantly reduce multiple risk factors without increasing the pill burden or the risk of adverse effects, has the potential to improve CV risk factor management, thereby reducing the incidence of CVD. This review discusses the benefits of the polypill and the challenges and requirements for its success and registerability. Discussions with regulatory bodies are required in order to obtain some 'balance' between an overcautious registration approach and the potentially large public health benefits that are likely to arise from the use of polypills.
Indexed as
Identifiers
16603580What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.